EP4435009A3 - Claudin6 antibodies and methods of treating cancer - Google Patents

Claudin6 antibodies and methods of treating cancer Download PDF

Info

Publication number
EP4435009A3
EP4435009A3 EP24169481.9A EP24169481A EP4435009A3 EP 4435009 A3 EP4435009 A3 EP 4435009A3 EP 24169481 A EP24169481 A EP 24169481A EP 4435009 A3 EP4435009 A3 EP 4435009A3
Authority
EP
European Patent Office
Prior art keywords
seq
claudin6
antibodies
methods
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24169481.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4435009A2 (en
Inventor
Dylan CONKLIN
Dennis Slamon
Neil O'Brien
Mike PALAZZOLO
Erika VON EUW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Publication of EP4435009A2 publication Critical patent/EP4435009A2/en
Publication of EP4435009A3 publication Critical patent/EP4435009A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
EP24169481.9A 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer Pending EP4435009A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
EP18857242.4A EP3826667B1 (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP18857242.4A Division EP3826667B1 (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer

Publications (2)

Publication Number Publication Date
EP4435009A2 EP4435009A2 (en) 2024-09-25
EP4435009A3 true EP4435009A3 (en) 2025-02-26

Family

ID=65723110

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24169481.9A Pending EP4435009A3 (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer
EP18857242.4A Active EP3826667B1 (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP18857242.4A Active EP3826667B1 (en) 2017-09-18 2018-09-18 Claudin6 antibodies and methods of treating cancer

Country Status (22)

Country Link
US (4) US20200291111A1 (cg-RX-API-DMAC7.html)
EP (2) EP4435009A3 (cg-RX-API-DMAC7.html)
JP (2) JP7599332B2 (cg-RX-API-DMAC7.html)
KR (2) KR102793719B1 (cg-RX-API-DMAC7.html)
CN (2) CN118667021A (cg-RX-API-DMAC7.html)
AU (2) AU2018334434B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020005196A2 (cg-RX-API-DMAC7.html)
CA (1) CA3076207A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2021138A3 (cg-RX-API-DMAC7.html)
DK (1) DK3826667T3 (cg-RX-API-DMAC7.html)
ES (1) ES2986343T3 (cg-RX-API-DMAC7.html)
FI (1) FI3826667T3 (cg-RX-API-DMAC7.html)
GB (1) GB202103867D0 (cg-RX-API-DMAC7.html)
HU (1) HUE067603T2 (cg-RX-API-DMAC7.html)
IL (2) IL273196B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020002921A (cg-RX-API-DMAC7.html)
NO (1) NO20210351A1 (cg-RX-API-DMAC7.html)
PL (1) PL3826667T3 (cg-RX-API-DMAC7.html)
PT (1) PT3826667T (cg-RX-API-DMAC7.html)
SG (1) SG11202002114RA (cg-RX-API-DMAC7.html)
SI (1) SI3826667T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019056023A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002921A (es) * 2017-09-18 2020-09-28 Univ California Anticuerpos para claudin6 y métodos para tratar el cáncer.
IL273471B2 (en) 2017-09-29 2023-09-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
SG11202108281UA (en) 2019-02-15 2021-08-30 Integral Molecular Inc Claudin 6 antibodies and uses thereof
JP7682797B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
JP7682798B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６抗体及び薬物複合体
JP2023529557A (ja) 2020-05-04 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗ｅｎｐｐ１抗体の阻害
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
US20250042996A1 (en) * 2021-11-16 2025-02-06 Christopher Bebbington Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
JP2025508362A (ja) * 2022-02-09 2025-03-26 セラ プログノスティックス， インコーポレイテッド Ｓｈｂｇおよびｉｂｐ４抗体、ならびにそれを使用する方法
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
WO2025146161A1 (en) * 2024-01-04 2025-07-10 Hansoh Bio Llc Antibody, antigen-binding fragment and medical use thereof
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087978A1 (ja) * 2008-01-11 2009-07-16 The University Of Tokyo 抗cldn6抗体
WO2012003956A1 (en) * 2010-07-06 2012-01-12 Ganymed Pharmaceuticals Ag Cancer therapy using cldn6 target-directed antibodies in vivo
WO2012156018A1 (en) * 2011-05-13 2012-11-22 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
WO2015069794A2 (en) * 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US6303144B1 (en) 1998-02-10 2001-10-16 Welfide Corporation Preparations with controlled release
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｖｉｐアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US7917208B2 (en) 2002-10-04 2011-03-29 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
JP5632582B2 (ja) * 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CA2942459C (en) * 2014-04-01 2023-03-07 Biontech Cell & Gene Therapies Gmbh Claudin-6-specific immunoreceptors and t cell epitopes
MX2020002921A (es) * 2017-09-18 2020-09-28 Univ California Anticuerpos para claudin6 y métodos para tratar el cáncer.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087978A1 (ja) * 2008-01-11 2009-07-16 The University Of Tokyo 抗cldn6抗体
WO2012003956A1 (en) * 2010-07-06 2012-01-12 Ganymed Pharmaceuticals Ag Cancer therapy using cldn6 target-directed antibodies in vivo
WO2012156018A1 (en) * 2011-05-13 2012-11-22 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
WO2015069794A2 (en) * 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use

Also Published As

Publication number Publication date
SG11202002114RA (en) 2020-04-29
WO2019056023A2 (en) 2019-03-21
KR102793719B1 (ko) 2025-04-08
BR112020005196A2 (pt) 2020-09-15
JP2024150445A (ja) 2024-10-23
AU2025200467A1 (en) 2025-04-10
IL313238A (en) 2024-07-01
GB202103867D0 (en) 2021-05-05
US20250333501A1 (en) 2025-10-30
IL273196B2 (en) 2024-11-01
SI3826667T1 (sl) 2024-09-30
CA3076207A1 (en) 2019-03-21
DK3826667T3 (da) 2024-07-22
MX2020002921A (es) 2020-09-28
PT3826667T (pt) 2024-08-02
MX2025012685A (es) 2025-11-03
US20200291111A1 (en) 2020-09-17
JP2020536507A (ja) 2020-12-17
FI3826667T3 (fi) 2024-07-22
ES2986343T3 (es) 2024-11-11
EP3826667A4 (en) 2022-07-27
PL3826667T3 (pl) 2024-09-30
EP3826667B1 (en) 2024-04-17
NO20210351A1 (en) 2021-03-18
CN111565744B (zh) 2024-12-31
US20240400674A1 (en) 2024-12-05
AU2018334434B2 (en) 2025-01-23
KR20200070238A (ko) 2020-06-17
CN111565744A (zh) 2020-08-21
KR20250050137A (ko) 2025-04-14
EP3826667A2 (en) 2021-06-02
IL273196B1 (en) 2024-07-01
WO2019056023A3 (en) 2019-05-16
EP4435009A2 (en) 2024-09-25
CZ2021138A3 (cs) 2021-09-15
HUE067603T2 (hu) 2024-10-28
AU2018334434A1 (en) 2020-04-02
US20220372134A1 (en) 2022-11-24
IL273196A (en) 2020-04-30
CN118667021A (zh) 2024-09-20
JP7599332B2 (ja) 2024-12-13

Similar Documents

Publication Publication Date Title
EP4435009A3 (en) Claudin6 antibodies and methods of treating cancer
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
MY200988A (en) CD3 Binding Antibodies
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
RU2016100892A (ru) Антитела против tweakr и их применение
NZ595235A (en) Compositions and methods for increasing muscle growth
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
SG151284A1 (en) Antibodies against ccr5 and uses thereof
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
NZ712765A (en) Antibodies that bind csf1r
WO2017060322A3 (en) Ptefb-inhibitor-adc
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3826667

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101AFI20250123BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116828

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250826

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20251105